Preoperative albumin to globulin ratio predicts survival in clear cell renal cell carcinoma patients. 2017

Zhen Chen, and Yingjie Shao, and Hongwei Yao, and Qianfeng Zhuang, and Kun Wang, and Zhaoyu Xing, and Xianlin Xu, and Xiaozhou He, and Renfang Xu
Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, P.R. China.

In this retrospective analysis, we evaluated associations between albumin to globulin ratio (AGR), clinicopathological characteristics, and survival in 592 patients with localized or locally advanced clear cell renal cell carcinoma (CCRCC) prior to nephrectomy. We found that low AGR was associated with more aggressive tumor behavior; patients with low AGR had poorer overall survival (OS) and cancer-specific survival (CSS) in Kaplan-Meier survival analyses both before and after propensity score matching, which was used to compensate for differences in baseline clinicopathological characteristics. AGR was an independent prognostic factor for both OS (HR: 6.799; 95% CI: 3.215-14.377; P < 0.001) and CSS (HR: 8.806; 95% CI: 3.891-19.928; P < 0.001), and its prognostic value was higher than that of other established inflammation-based prognostic scores. When AGR was incorporated into a prognostic model that included T stage, neutrophil to lymphocyte ratio (NLR), and monocyte to lymphocyte ratio (MLR), the resulting nomogram predicted 3- and 5-year OS in the patients more accurately than when AGR was not included. In conclusion, AGR may be particularly useful for improving clinical outcome predictions for patients with localized or locally advanced CCRCC.

UI MeSH Term Description Entries
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002292 Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. Adenocarcinoma, Renal Cell,Carcinoma, Hypernephroid,Grawitz Tumor,Hypernephroma,Renal Carcinoma,Adenocarcinoma Of Kidney,Adenocarcinoma, Renal,Chromophil Renal Cell Carcinoma,Chromophobe Renal Cell Carcinoma,Clear Cell Renal Carcinoma,Clear Cell Renal Cell Carcinoma,Collecting Duct Carcinoma,Collecting Duct Carcinoma (Kidney),Collecting Duct Carcinoma of the Kidney,Nephroid Carcinoma,Papillary Renal Cell Carcinoma,Renal Cell Cancer,Renal Cell Carcinoma,Renal Cell Carcinoma, Papillary,Renal Collecting Duct Carcinoma,Sarcomatoid Renal Cell Carcinoma,Adenocarcinoma Of Kidneys,Adenocarcinomas, Renal Cell,Cancer, Renal Cell,Carcinoma, Collecting Duct,Carcinoma, Collecting Duct (Kidney),Carcinoma, Nephroid,Carcinoma, Renal,Carcinomas, Collecting Duct,Carcinomas, Collecting Duct (Kidney),Carcinomas, Renal Cell,Collecting Duct Carcinomas,Collecting Duct Carcinomas (Kidney),Hypernephroid Carcinoma,Hypernephroid Carcinomas,Hypernephromas,Kidney, Adenocarcinoma Of,Nephroid Carcinomas,Renal Adenocarcinoma,Renal Adenocarcinomas,Renal Carcinomas,Renal Cell Adenocarcinoma,Renal Cell Adenocarcinomas,Renal Cell Cancers,Renal Cell Carcinomas,Tumor, Grawitz
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Zhen Chen, and Yingjie Shao, and Hongwei Yao, and Qianfeng Zhuang, and Kun Wang, and Zhaoyu Xing, and Xianlin Xu, and Xiaozhou He, and Renfang Xu
January 2018, International braz j urol : official journal of the Brazilian Society of Urology,
Zhen Chen, and Yingjie Shao, and Hongwei Yao, and Qianfeng Zhuang, and Kun Wang, and Zhaoyu Xing, and Xianlin Xu, and Xiaozhou He, and Renfang Xu
March 2019, Journal of cellular physiology,
Zhen Chen, and Yingjie Shao, and Hongwei Yao, and Qianfeng Zhuang, and Kun Wang, and Zhaoyu Xing, and Xianlin Xu, and Xiaozhou He, and Renfang Xu
January 2017, Journal of Cancer,
Zhen Chen, and Yingjie Shao, and Hongwei Yao, and Qianfeng Zhuang, and Kun Wang, and Zhaoyu Xing, and Xianlin Xu, and Xiaozhou He, and Renfang Xu
May 2016, Oncotarget,
Zhen Chen, and Yingjie Shao, and Hongwei Yao, and Qianfeng Zhuang, and Kun Wang, and Zhaoyu Xing, and Xianlin Xu, and Xiaozhou He, and Renfang Xu
September 2025, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery,
Zhen Chen, and Yingjie Shao, and Hongwei Yao, and Qianfeng Zhuang, and Kun Wang, and Zhaoyu Xing, and Xianlin Xu, and Xiaozhou He, and Renfang Xu
March 2021, Turkish journal of urology,
Zhen Chen, and Yingjie Shao, and Hongwei Yao, and Qianfeng Zhuang, and Kun Wang, and Zhaoyu Xing, and Xianlin Xu, and Xiaozhou He, and Renfang Xu
November 2014, Urologic oncology,
Zhen Chen, and Yingjie Shao, and Hongwei Yao, and Qianfeng Zhuang, and Kun Wang, and Zhaoyu Xing, and Xianlin Xu, and Xiaozhou He, and Renfang Xu
January 2016, PeerJ,
Zhen Chen, and Yingjie Shao, and Hongwei Yao, and Qianfeng Zhuang, and Kun Wang, and Zhaoyu Xing, and Xianlin Xu, and Xiaozhou He, and Renfang Xu
February 2021, Translational andrology and urology,
Zhen Chen, and Yingjie Shao, and Hongwei Yao, and Qianfeng Zhuang, and Kun Wang, and Zhaoyu Xing, and Xianlin Xu, and Xiaozhou He, and Renfang Xu
May 2019, Future oncology (London, England),
Copied contents to your clipboard!